Management of advanced heart failure: a review

References

• Fang JC, Ewald GA, Allen LA, et al. Advanced (stage D) heart failure: a statement from the Heart Failure Society Of America Guidelines Committee. J Card Fail. 2015 Jun;21(6):519–534. doi: 10.1016/j.cardfail.2015.04.013.
   PubMed Web of Science ®Google Scholar
• Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: A position statement from the study group on advanced heart failure of the heart failure association of the European society of cardiology. Eur J Heart Fail. 2007 Jun-Jul;9(6–7):684–694. eng.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017 Mar 07;135(10):e146–e603. PubMed Central PMCID: PMCPMC5408160. eng.
   PubMed Web of Science ®Google Scholar
• Maggioni AP. Epidemiology of Heart Failure in Europe. Heart Fail Clin. 2015 Oct;11(4):625–635. eng.
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014 Apr 01;63(12):1123–1133. eng.
   PubMed Web of Science ®Google Scholar
• Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011 Jan 8;8(1):30–41. PubMed Central PMCID: PMCPMC3033496. eng.
   PubMed Web of Science ®Google Scholar
• Roger VL. Epidemiology of heart failure. Circ Res. 2013 Aug 30;113(6):646–659. PubMed Central PMCID: PMCPMC3806290. eng.
   PubMed Web of Science ®Google Scholar
• Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994–2003. Arch Intern Med. 2008 Feb 25;168(4):418–424. eng.
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep. 2014 Dec;11(4):404–415. PubMed Central PMCID: PMCPMC4224604. eng.
   PubMedGoogle Scholar
• Abouezzeddine OF, Redfield MM. Who has advanced heart failure?: definition and epidemiology. Congest Heart Fail. 2011 Jul-Aug;17(4):160–168. PubMed Central PMCID: PMCPMC3857759. eng.
   PubMedGoogle Scholar
• Bjork JB, Alton KK, Georgiopoulou VV, et al. Defining advanced heart failure: a systematic review of criteria used in clinical trials. J Card Fail. 2016 Jul;22(7):569–577. eng.
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Mills RM, Wynne J. Characteristics of “Stage D” heart failure: insights from the acute decompensated heart failure national registry longitudinal module (ADHERE LM). Am Heart J. 2008 Feb;155(2):339–347. eng.
   PubMed Web of Science ®Google Scholar
• Norton C, Georgiopoulou VV, Kalogeropoulos AP, et al. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis. 2011 Sep-Oct;54(2):78–85. eng.
   PubMed Web of Science ®Google Scholar
• Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the flolan international randomized survival trial (FIRST). Am Heart J. 1997 Jul;134(1):44–54. eng.
   PubMed Web of Science ®Google Scholar
• Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College Of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation. 2007 Mar 27;115(12):1563–1570. eng.
   PubMed Web of Science ®Google Scholar
• Reyentovich A, Barghash MH, Hochman JS. Management of refractory cardiogenic shock. Nat Rev Cardiol. 2016 Aug;13(8):481–492. eng.
   PubMed Web of Science ®Google Scholar
• Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008 Feb 05;117(5):686–697. eng.
   PubMed Web of Science ®Google Scholar
• Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999 Aug 26;341(9):625–634. eng.
   PubMed Web of Science ®Google Scholar
• Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. Jama. 2001 Jan 10;285(2):190–192. eng.
   PubMed Web of Science ®Google Scholar
• Shah P, Cowger JA. Cardiogenic shock. Crit Care Clin. 2014 Jul;30(3):391–412. eng.
   PubMed Web of Science ®Google Scholar
• Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003 Jun 24;107(24):2998–3002. eng.
   PubMed Web of Science ®Google Scholar
• Tharmaratnam D, Nolan J, Jain A. Management of cardiogenic shock complicating acute coronary syndromes. Heart. 2013 Nov;99(21):1614–1623. eng.
   PubMed Web of Science ®Google Scholar
• Kalmanovich E, Blatt A, Brener S, et al. Trends in the management and outcomes of patients admitted with acute coronary syndrome complicated by cardiogenic shock over the past decade: real world data from the acute coronary syndrome Israeli survey (ACSIS). Oncotarget. 2017 Jun 27;8(26):42876–42886. PubMed Central PMCID: PMCPMC5522112. eng.
   PubMedGoogle Scholar
• Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation. 2009 Mar 10;119(9):1211–1219. PubMed Central PMCID: PMCPMC2730832. eng.
   PubMed Web of Science ®Google Scholar
• Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014 Jan 13;3(1):e000590. PubMed Central PMCID: PMCPMC3959706. eng.
   PubMed Web of Science ®Google Scholar
• Aissaoui N, Puymirat E, Tabone X, et al. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries. Eur Heart J. 2012 Oct;33(20):2535–2543. eng.
   PubMed Web of Science ®Google Scholar
• Chaudhry SP, Stewart GC. Advanced heart failure: prevalence, natural history, and prognosis. Heart Fail Clin. 2016 Jul;12(3):323–333. eng.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891–975. eng.
   PubMed Web of Science ®Google Scholar
• Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme–a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003 Mar;24(5):464–474. eng.
   PubMed Web of Science ®Google Scholar
• Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005 Aug;26(16):1653–1659. eng.
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651–1658. eng.
   PubMed Web of Science ®Google Scholar
• Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol. 2001 Oct;38(4):932–938. eng.
   PubMed Web of Science ®Google Scholar
• The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 02;353(9146):9–13. eng.
   PubMed Web of Science ®Google Scholar
• Investigators TB-BEoST. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England J Med. 2001;344(22): 1659–1667.
   PubMed Web of Science ®Google Scholar
• Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001 Nov 15;345(20):1435–1443. eng.
   PubMed Web of Science ®Google Scholar
• CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429–1435. eng.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 Sep 03;327(10):685–691. eng.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north scandinavian enalapril survival study (CONSENSUS). Am J Cardiol. 1988 Jul 11;62(2):60a–66a. eng.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec 06;345(23):1667–1675. eng.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 Sep 06;362(9386):767–771. eng.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999 Sep 02;341(10):709–717. eng.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 03;348(14):1309–1321. eng.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993–1004. eng.
   PubMed Web of Science ®Google Scholar
• Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997 Feb 20;336(8):525–533. eng.
   PubMed Web of Science ®Google Scholar
• Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. Jama. 2003 Feb 19;289(7):871–878. eng.
   PubMed Web of Science ®Google Scholar
• Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. Bmj. 2015 Aug 30;351:h4451. doi:10.1136/bmj.h4451.
   PubMedGoogle Scholar
• Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015 Jul 21;36(28):1831–1838. eng.
   PubMed Web of Science ®Google Scholar
• Hood WB Jr., Dans AL, Guyatt GH, et al. Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database Syst Rev. 2014 Apr;28(4):Cd002901. eng.
   Google Scholar
• Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993 Oct;22(4):955–962. eng.
   PubMed Web of Science ®Google Scholar
• Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993 Jul 01;329(1):1–7. eng.
   PubMed Web of Science ®Google Scholar
• Hopper I, Samuel R, Hayward C, et al. Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysis. J Card Fail. 2014 Jul;20(7):522–532. eng.
   PubMed Web of Science ®Google Scholar
• Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012 Feb;15(2):Cd003838. eng.
   Google Scholar
• Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 03;364(9):797–805. PubMed Central PMCID: PMCPMC3412356. eng.
   PubMed Web of Science ®Google Scholar
• Pruett AE, Lee AK, Patterson JH, et al. Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence. Curr Cardiol Rev. 2015;11(1):80–89. PubMed Central PMCID: PMCPMC4347213. eng
   PubMed Web of Science ®Google Scholar
• Curinier C, Solecki K, Dupuy AM, et al. Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: study protocol for a randomized controlled trial. Contemp Clin Trials. 2018 Mar;66:45–50. eng.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011 Feb 19;377(9766):658–666. eng.
   PubMed Web of Science ®Google Scholar
• Mielniczuk LM, Tsang SW, Desai AS, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008 Jun;14(5):388–393. eng.
   PubMed Web of Science ®Google Scholar
• Neuberg GW, Miller AB, O’Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002 Jul;144(1):31–38. eng.
   PubMed Web of Science ®Google Scholar
• Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 2003 Aug 20;42(4):705–708. eng.
   PubMed Web of Science ®Google Scholar
• Domanski M, Tian X, Haigney M, et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail. 2006 Jun;12(5):327–332. eng.
   PubMed Web of Science ®Google Scholar
• Kimura M, Kohno T, Murata M, et al. Oral nitrate administration ameliorates cardiogenic shock due to eclipsed mitral regurgitation. Cardiology. 2016;134(3):327–330. eng.
   PubMed Web of Science ®Google Scholar
• Lenders GD, Jorens PG, De Meyer T, et al. Coronary spasm after the topical use of cocaine in nasal surgery. Am J Case Rep. 2013;14:76–79. PubMed Central PMCID: PMCPMC3619047. eng.
   PubMedGoogle Scholar
• Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N Engl J Med. 1986 Jun 12;314(24):1547–1552. eng.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. eng.
   PubMed Web of Science ®Google Scholar
• Elkayam U, Bitar F. Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial. Am J Cardiol. 2005 Oct 10;96(7b):37i–43i. eng.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004 Nov 11;351(20):2049–2057. eng.
   PubMed Web of Science ®Google Scholar
• Farag M, Mabote T, Shoaib A, et al. Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. Int J Cardiol. 2015 Oct;1(196):61–69. eng.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129–2200. eng.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147–239. PubMed PMID: 23747642.
   PubMed Web of Science ®Google Scholar
• Chaudhary R, Garg J, Krishnamoorthy P, et al. Ivabradine: heart failure and beyond. J Cardiovasc Pharmacol Ther. 2016 Jul;21(4):335–343. eng.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 Sep 11;376(9744):875–885. eng.
   PubMed Web of Science ®Google Scholar
• Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail. 2009 Jul 2;(4):320–324. eng. DOI:10.1161/circheartfailure.108.839076
   PubMed Web of Science ®Google Scholar
• Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. Eur Heart J. 2011 Aug;32(15):1838–1845. eng.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999 Jul;138(1 Pt 1):78–86. eng.
   PubMed Web of Science ®Google Scholar
• Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002 Aug 4;4:515–529. eng.
   PubMed Web of Science ®Google Scholar
• Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med. 2012 Mar;38(3):359–367. eng.
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. Jama. 2002 Mar 27;287(12):1541–1547. eng.
   PubMed Web of Science ®Google Scholar
• Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003 Mar 19;41(6):997–1003. eng.
   PubMed Web of Science ®Google Scholar
• Papp Z, Edes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012 Aug 23;159(2):82–87. eng.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000 Nov 15;36(6):1903–1912. eng.
   PubMed Web of Science ®Google Scholar
• Kivikko M, Antila S, Eha J, et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002 Oct;40(10):465–471. eng.
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002 Jul 20;360(9328):196–202. eng.
   PubMed Web of Science ®Google Scholar
• Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002 Sep;23(18):1422–1432. eng.
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013 Apr 1;(2):103–111. eng. DOI:10.1016/j.jchf.2012.12.004
   PubMed Web of Science ®Google Scholar
• Pollesello P, Parissis J, Kivikko M, et al. Levosimendan meta-analyses: is there a pattern in the effect on mortality? Int J Cardiol. 2016 Apr;15(209):77–83. eng.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Felker GM, McMurray JJ, et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016 Dec 10;388(10062):2895–2903. eng.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Felker GM, McMurray JJV, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol. 2016 Mar 29;67(12):1444–1455. eng.
   PubMed Web of Science ®Google Scholar
• Pieske B, Butler J, Filippatos G, et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep;16(9):1026–1038. eng.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. Jama. 2015 Dec 1;314(21):2251–2262. eng.
   PubMed Web of Science ®Google Scholar
• Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017 Apr 14;38(15):1119–1127. PubMed Central PMCID: PMCPMC5400074. eng.
   PubMed Web of Science ®Google Scholar
• Kim DH, Chien FJ, Eisen HJ. Pharmacologic management for heart failure and emerging therapies. Curr Cardiol Rep. 2017 Aug 24;19(10):94. eng.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013 Jan 5;381(9860):29–39. eng.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Voors AA, Ponikowski P, et al. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail. 2017 Jun;19(6):800–809. PubMed Central PMCID: PMCPMC5488179. eng.
   PubMed Web of Science ®Google Scholar
• Rosenstein R, Hough A. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016 Mar 17;374(11):1093–1094. eng.
   PubMedGoogle Scholar
• Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015 March 31;65(12):1231–1248.
   PubMed Web of Science ®Google Scholar
• Lüscher TF. Frontiers of valvular heart disease: from aortic stenosis to the tricuspid valve and congenital anomalies. Eur Heart J. 2017;38(9):611–614.
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed). 2015 Feb;68(2):144. eng.
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011 Apr 28;364(17):1607–1616. PubMed Central PMCID: PMCPMC3415273. eng.
   PubMed Web of Science ®Google Scholar
• Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017 Dec 21;377(25):2419–2432. eng.
   PubMed Web of Science ®Google Scholar
• Burri H, Prinzen FW, Gasparini M, et al. Left univentricular pacing for cardiac resynchronization therapy. Europace. 2017 Jun 1;19(6):912–919. eng.
   PubMed Web of Science ®Google Scholar
• Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society Of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013 Aug;15(8):1070–1118. eng.
   PubMedGoogle Scholar
• Keteyian SJ, Pina IL, Hibner BA, et al. Clinical role of exercise training in the management of patients with chronic heart failure. J Cardiopulm Rehabil Prev. 2010 Mar-Apr;30(2):67–76. eng.
   PubMed Web of Science ®Google Scholar
• Crimi E, Ignarro LJ, Cacciatore F, et al. Mechanisms by which exercise training benefits patients with heart failure. Nat Rev Cardiol. 2009 Apr 6;(4):292–300. eng. DOI:10.1038/nrcardio.2009.8
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. Jama. 2009 Apr 08;301(14):1439–1450. PubMed Central PMCID: PMCPMC2916661. eng.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014 Apr;27(4):Cd003331. eng.
   Google Scholar
• Erbs S, Hollriegel R, Linke A, et al. Exercise training in patients with advanced chronic heart failure (NYHA IIIb) promotes restoration of peripheral vasomotor function, induction of endogenous regeneration, and improvement of left ventricular function. Circ Heart Fail. 2010 Jul;3(4):486–494. eng.
   PubMed Web of Science ®Google Scholar
• Michio Nakanishi RK, Arakawa T, Noguchi T, et al. Exercise training in advanced heart failure patients with severely reduced left ventricular ejection fraction. J Card Fail. 2013;19(10):S111.
   Web of Science ®Google Scholar
• Kerrigan DJ, Williams CT, Ehrman JK, et al. Cardiac rehabilitation improves functional capacity and patient-reported health status in patients with continuous-flow left ventricular assist devices: the Rehab-VAD randomized controlled trial. JACC Heart Fail. 2014 Dec 2;(6):653–659. eng. DOI:10.1016/j.jchf.2014.06.011
   PubMed Web of Science ®Google Scholar
• Ganga HV, Leung A, Jantz J, et al. Supervised exercise training versus usual care in ambulatory patients with left ventricular assist devices: A systematic review. PLoS One. 2017;12(3):e0174323. PubMed Central PMCID: PMCPMC5375157. eng.
   PubMed Web of Science ®Google Scholar
• Hogness JRVM. Institute of Medicine (US) Committee to evaluate the artificial heart program of the national heart, lung, and blood institute. Washington (DC): National Academies Press (US); 1991.
   Google Scholar
• DeVries WC, Anderson JL, Joyce LD, et al. Clinical use of the total artificial heart. N Engl J Med. 1984 Feb 2;310(5):273–278. eng.
   PubMed Web of Science ®Google Scholar
• Portner PM, Oyer PE, Pennington DG, et al. Implantable electrical left ventricular assist system: bridge to transplantation and the future. Ann Thorac Surg. 1989 Jan;47(1):142–150. eng.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Smith SA. Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol. 2013 Feb;10(2):98-110. DOI:10.1038/nrcardio.2012.178
   Google Scholar
• Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N Engl J Med. 1998 Nov 19;339(21):1522–1533. eng.
   PubMed Web of Science ®Google Scholar
• McCarthy PM, Sabik JF. Implantable circulatory support devices as a bridge to heart transplantation. Semin Thorac Cardiovasc Surg. 1994 Jul;6(3):174–180. eng.
   PubMedGoogle Scholar
• Birks EJ, Tansley PD, Yacoub MH, et al. Incidence and clinical management of life-threatening left ventricular assist device failure. J Heart Lung Transplant. 2004 Aug;23(8):964–969. eng.
   PubMed Web of Science ®Google Scholar
• Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009 Dec 03;361(23):2241–2251. eng.
   PubMed Web of Science ®Google Scholar
• Sheikh FH, Russell SD. HeartMate(R) II continuous-flow left ventricular assist system. Expert Rev Med Devices. 2011 Jan 8;1:11–21. eng.
   PubMed Web of Science ®Google Scholar
• Jaquiss RD, Imamura M. Implantation of a Berlin heart ventricular assist device. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2011;14(1):120–125. eng.
   PubMedGoogle Scholar
• Timms D. A review of clinical ventricular assist devices. Med Eng Phys. 2011 Nov;33(9):1041–1047. eng.
   PubMed Web of Science ®Google Scholar
• Sale SM, Smedira NG. Total artificial heart. Best Pract Res Clin Anaesthesiol. 2012 Jun;26(2):147–165. eng.
   PubMedGoogle Scholar
• Copeland JG, Arabia FA, Tsau PH, et al. Total artificial hearts: bridge to transplantation. Cardiol Clin. 2003 Feb;21(1):101–113. eng.
   PubMedGoogle Scholar
• Meyer A, Slaughter M. The total artificial heart. Panminerva Med. 2011 Sep;53(3):141–154. eng.
   PubMed Web of Science ®Google Scholar
• Smadja DM, Susen S, Rauch A, et al. The carmat bioprosthetic total artificial heart is associated with early hemostatic recovery and no acquired von willebrand syndrome in calves. J Cardiothorac Vasc Anesth. 2017 Oct;31(5):1595–1602. eng.
   PubMed Web of Science ®Google Scholar
• Latremouille C, Carpentier A, Leprince P, et al. A bioprosthetic total artificial heart for end-stage heart failure: results from a pilot study. J Heart Lung Transplant. 2017 Sep 14. eng. DOI:10.1016/j.healun.2017.09.002
   Web of Science ®Google Scholar
• Puckett C, Mudd JO. Tailoring therapies in advanced heart failure. Heart Fail Clin. 2016 Jul;12(3):375–384. eng.
   PubMed Web of Science ®Google Scholar
• Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017 Oct;36(10):1080–1086. eng.
   PubMed Web of Science ®Google Scholar
• van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017 Oct 17;136(16):e232–e268. eng.
   PubMed Web of Science ®Google Scholar
• Brown JL, Estep JD. Temporary percutaneous mechanical circulatory support in advanced heart failure. Heart Fail Clin. 2016 Jul;12(3):385–398. eng.
   PubMed Web of Science ®Google Scholar
• Mandawat A, Rao SV. Percutaneous mechanical circulatory support devices in cardiogenic shock. Circ Cardiovasc Interv. 2017 May;10(5). PubMed Central PMCID: PMCPMC5578718. eng. DOI:10.1161/circinterventions.116.004337
   PubMed Web of Science ®Google Scholar
• Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society For Heart And Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013 Feb;32(2):157–187. eng.
   PubMed Web of Science ®Google Scholar
• Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation. 2012 Nov 27;126(22):2648–2667. eng.
   PubMed Web of Science ®Google Scholar
• Ouweneel DM, Henriques JP. Percutaneous cardiac support devices for cardiogenic shock: current indications and recommendations. Heart. 2012 Aug;98(16):1246–1254. eng.
   PubMed Web of Science ®Google Scholar
• Feldman D, Menachemi DM, Abraham WT, et al. Management strategies for stage-D patients with acute heart failure. Clin Cardiol. 2008 Jul;31(7):297–301. PubMed Central PMCID: PMCPMC2692105. eng.
   PubMed Web of Science ®Google Scholar
• Unverzagt S, Buerke M, de Waha A, et al. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev. 2015 Mar;27(3):Cd007398. eng.
   Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society Of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119–177. eng.
   PubMed Web of Science ®Google Scholar
• Kapelios CJ, Terrovitis JV, Nanas JN. Current and future applications of the intra-aortic balloon pump. Curr Opin Cardiol. 2014 May;29(3):258–265. eng.
   PubMed Web of Science ®Google Scholar
• Gjesdal O, Gude E, Arora S, et al. Intra-aortic balloon counterpulsation as a bridge to heart transplantation does not impair long-term survival. Eur J Heart Fail. 2009 Jul;11(7):709–714. eng.
   PubMed Web of Science ®Google Scholar
• Raess DH, Weber DM. Impella 2.5. J Cardiovasc Transl Res. 2009 Jun 2;2:168–172. eng.
   PubMed Web of Science ®Google Scholar
• Kapur NK, Esposito ML, Bader Y, et al. Mechanical circulatory support devices for acute right ventricular failure. Circulation. 2017 Jul 18;136(3):314–326. eng.
   PubMed Web of Science ®Google Scholar
• Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008 Nov 04;52(19):1584–1588. eng.
   PubMed Web of Science ®Google Scholar
• Ouweneel DM, Eriksen E, Seyfarth M, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump for treating cardiogenic shock: meta-analysis. J Am Coll Cardiol. 2017 Jan 24;69(3):358–360. eng.
   PubMed Web of Science ®Google Scholar
• Ouweneel DM, Engstrom AE, Sjauw KD, et al. Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial. Int J Cardiol. 2016 Jan;01(202):894–896. eng.
   PubMed Web of Science ®Google Scholar
• Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017 Jan 24;69(3):278–287. PubMed PMID: 27810347.
   PubMed Web of Science ®Google Scholar
• Lauten A, Engstrom AE, Jung C, et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail. 2013 Jan 6;(1):23–30. eng. DOI:10.1161/circheartfailure.112.967224
   PubMed Web of Science ®Google Scholar
• Casassus F, Corre J, Leroux L, et al. The use of Impella 2.5 in severe refractory cardiogenic shock complicating an acute myocardial infarction. J Interv Cardiol. 2015 Feb;28(1):41–50. eng.
   PubMed Web of Science ®Google Scholar
• O’Neill WW, Schreiber T, Wohns DH, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella registry. J Interv Cardiol. 2014 Feb;27(1):1–11. PubMed Central PMCID: PMCPMC4238821. eng.
   PubMed Web of Science ®Google Scholar
• Engstrom AE, Cocchieri R, Driessen AH, et al. The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: the academic medical center intensive care unit experience. Crit Care Med. 2011 Sep;39(9):2072–2079. eng.
   PubMed Web of Science ®Google Scholar
• Lemaire A, Anderson MB, Lee LY, et al. The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. Ann Thorac Surg. 2014 Jan;97(1):133–138. PubMed PMID: 24090575
   PubMed Web of Science ®Google Scholar
• Griffith BP, Anderson MB, Samuels LE, et al. The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg. 2013 Feb;145(2):548–554. eng.
   PubMed Web of Science ®Google Scholar
• Mastroianni C, Bouabdallaoui N, Leprince P, et al. Short-term mechanical circulatory support with the Impella 5.0 device for cardiogenic shock at La Pitie-Salpetriere. Eur Heart J Acute Cardiovasc Care. 2017 Feb 6;(1):87–92. eng. DOI:10.1177/2048872616633877
   PubMed Web of Science ®Google Scholar
• Lima B, Kale P, Gonzalez-Stawinski GV, et al. Effectiveness and safety of the Impella 5.0 as a bridge to cardiac transplantation or durable left ventricular assist device. Am J Cardiol. 2016 May 15;117(10):1622–1628. eng.
   PubMed Web of Science ®Google Scholar
• Bansal A, Bhama JK, Patel R, et al. Using the minimally invasive Impella 5.0 via the right subclavian artery cutdown for acute on chronic decompensated heart failure as a bridge to decision. Ochsner J. 2016 Fall;16(3):210–216. PubMed Central PMCID: PMCPMC5024800. eng.
   PubMed Web of Science ®Google Scholar
• Den Uil CA, Akin S, Jewbali LS, et al. Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2017 Jul 01;52(1):14–25. eng.
   PubMed Web of Science ®Google Scholar
• Cheung AW, White CW, Davis MK, et al. Short-term mechanical circulatory support for recovery from acute right ventricular failure: clinical outcomes. J Heart Lung Transplant. 2014 Aug;33(8):794–799. eng.
   PubMed Web of Science ®Google Scholar
• Anderson MB, Goldstein J, Milano C, et al. Benefits of a novel percutaneous ventricular assist device for right heart failure: the prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant. 2015 Dec;34(12):1549–1560. eng.
   PubMed Web of Science ®Google Scholar
• Yan I, Grahn H, Blankenberg S, et al. Right ventricular temporal assist device for cardiac recompensation. ESC Heart Fail. 2017 Aug 4;(3):376–378. PubMed Central PMCID: PMCPMC5542743. eng. DOI:10.1002/ehf2.12148
   PubMed Web of Science ®Google Scholar
• Kuchibhotla S, Esposito ML, Breton C, et al. Acute biventricular mechanical circulatory support for cardiogenic shock. J Am Heart Assoc. 2017 Oct 20;6(10). PubMed PMID: 29054842; PubMed Central PMCID: PMCPMC5721869 DOI:10.1161/JAHA.117.006670
   PubMed Web of Science ®Google Scholar
• Kar B, Gregoric ID, Basra SS, et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol. 2011 Feb 08;57(6):688–696. eng.
   PubMed Web of Science ®Google Scholar
• Werdan K, Gielen S, Ebelt H, et al. Mechanical circulatory support in cardiogenic shock. Eur Heart J. 2014 Jan;35(3):156–167. eng.
   PubMed Web of Science ®Google Scholar
• Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006 Sep;152(3):469.e1–8. eng.
   PubMed Web of Science ®Google Scholar
• Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005 Jul;26(13):1276–1283. eng.
   PubMed Web of Science ®Google Scholar
• Bruckner BA, Jacob LP, Gregoric ID, et al. Clinical experience with the TandemHeart percutaneous ventricular assist device as a bridge to cardiac transplantation. Tex Heart Inst J. 2008;35(4):447–450. PubMed Central PMCID: PMCPMC2607106. eng.
   PubMed Web of Science ®Google Scholar
• Gregoric ID, Jacob LP, La Francesca S, et al. The TandemHeart as a bridge to a long-term axial-flow left ventricular assist device (bridge to bridge). Tex Heart Inst J. 2008;35(2):125–129. PubMed Central PMCID: PMCPMC2435454. eng.
   PubMed Web of Science ®Google Scholar
• Velez-Martinez M, Rao K, Warner J, et al. Successful use of the TandemHeart percutaneous ventricular assist device as a bridge to recovery for acute cellular rejection in a cardiac transplant patient. Transplant Proc. 2011 Dec;43(10):3882–3884. eng.
   PubMed Web of Science ®Google Scholar
• Baran DA. Extracorporeal membrane oxygenation (ECMO) and the critical cardiac patient. Curr Transplant Rep. 2017;4(3):218–225. PubMed Central PMCID: PMCPMC5577059. eng.
   PubMedGoogle Scholar
• Chamogeorgakis T, Rafael A, Shafii AE, et al. Which is better: a miniaturized percutaneous ventricular assist device or extracorporeal membrane oxygenation for patients with cardiogenic shock? Asaio j. 2013 Nov-Dec;59(6):607–611. eng.
   PubMed Web of Science ®Google Scholar
• Ouweneel DM, Schotborgh JV, Limpens J, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. 2016 Dec;42(12):1922–1934. PubMed Central PMCID: PMCPMC5106498. eng.
   PubMed Web of Science ®Google Scholar
• Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet. 2008 Aug 16;372(9638):554–561. eng.
   PubMed Web of Science ®Google Scholar
• Thiagarajan RR, Brogan TV, Scheurer MA, et al. Extracorporeal membrane oxygenation to support cardiopulmonary resuscitation in adults. Ann Thorac Surg. 2009 Mar;87(3):778–785. eng.
   PubMed Web of Science ®Google Scholar
• Combes A, Leprince P, Luyt CE, et al. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med. 2008 May;36(5):1404–1411. eng.
   PubMed Web of Science ®Google Scholar
• Mourad M, Gaudard P, De La Arena P, et al. Circulatory support with extracorporeal membrane oxygenation and/or impella for cardiogenic shock during myocardial infarction. Asaio j. 2017 Dec 11. eng. DOI:10.1097/mat.0000000000000704
   PubMedGoogle Scholar
• Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society For Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016 Jan;35(1):1–23. eng.
   PubMed Web of Science ®Google Scholar